MDAIHealthcare · Medical DevicesThe 1 Wall Street analysts covering Spectral AI, Inc. hold a median 12-month price target of $5.13 — +222.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Spectral AI, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (82): Smaller than most of the companies we track.
Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MDAI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +222.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 May 2026 | BTIG | Maintains | Buy | $3.00 → $4.00 |
| 26 May 2026 | BTIG | Maintains | Buy | $3.00 → $4.00 |
| 25 Mar 2026 | BTIG | Reiterates | Buy | — |
| 10 Feb 2026 | BTIG | Reiterates | Buy | — |
| 12 Nov 2025 | BTIG | Maintains | Buy | — |
| 2 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Aug 2024 | Northland Capital Markets | Initiates | Outperform | — |
| 18 July 2024 | HC Wainwright & Co. | Initiates | Buy | — |
| 23 Jan 2024 | BTIG | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MDAI appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 27% of US stocks
Cheaper than 38% of US stocks
Cheaper than 97% of US stocks
Cheaper than 78% of US stocks
Higher than 9% of US stocks
Higher than 12% of US stocks
Higher than 63% of US stocks
Higher than 13% of US stocks
Higher than 8% of US stocks
Higher than 97% of US stocks
Higher than 10% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Spectral AI, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Spectral AI, Inc. (MDAI) released the transcript of its Q2 2026 earnings call, published by Seeking Alpha. The item reports on the company's second-quarter 2026 earnings call taking place.
Why it matters — The earnings call transcript provides MDAI watchers with a record of what management communicated about the company's Q2 2026 results and outlook.
Spectral AI reported second-quarter results marking a transition toward commercial operations following the FDA's De Novo clearance of its DeepView System for burn assessment in May. The company reiterated its 2026 revenue guidance of approximately $18.5 million, which does not assume significant revenue from DeepView system sales.
Why it matters — A MDAI watcher would care because the earnings call confirms the company's shift from development to commercial operations and reaffirms its forward revenue guidance following regulatory clearance.
Spectral AI reported its Q2 2026 financial results, highlighting a cash position of $14.0 million as of June 30, 2026, and said it is continuing to advance toward first commercial sales of its DeepView System for burn indication.
Why it matters — The update signals Spectral AI's financial stability and commercial progress toward launching its lead product, the DeepView System, which is a key milestone for the company.
Spectral AI announced it will release its second quarter 2026 financial results on August 11, 2026 after market close, and will hold a conference call at 5:00 pm ET that same day to discuss the results.
Why it matters — The announcement provides the date and time for the company's quarterly financial update and investor call, which shareholders and analysts will watch for updates on Spectral AI's performance and outlook.
The 1 Wall Street analysts covering Spectral AI, Inc. have a median 12-month price target of $5.13, with estimates ranging from $4 to $6.25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Spectral AI, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Spectral AI, Inc. 16 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Spectral AI, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (82 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +222.3% from the last close, and Ticker Nerd's factor model ranks Spectral AI, Inc. 16 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Spectral AI, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MDAI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $6.25 over the next 12 months.
Spectral AI, Inc. returned -21.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Spectral AI Inc. is a cutting-edge technology company that specializes in the development of advanced imaging systems and artificial intelligence applications.
The most recent item we track (Seeking Alpha, 12 Aug 2026): "Spectral AI, Inc. (MDAI) Q2 2026 Earnings Call Transcript". Spectral AI, Inc. (MDAI) released the transcript of its Q2 2026 earnings call, published by Seeking Alpha. The item reports on the company's second-quarter 2026 earnings call taking place.
Spectral AI Inc. is a cutting-edge technology company that specializes in the development of advanced imaging systems and artificial intelligence applications. The primary function of Spectral AI is to transform medical diagnostics and clinical outcomes through its proprietary technology platform, which integrates imaging technologies with deep learning algorithms. Notable within the healthcare industry, this platform is particularly impactful in the diagnosis of burn wounds and chronic wounds, offering significant advancements over traditional methods. Spectral AI's technology facilitates real-time, non-invasive assessment, potentially improving decision-making for healthcare professionals. The company's innovations cater to the needs of hospitals, clinics, and military medical services, aiming to enhance patient care efficiency and outcomes dramatically. In the financial market, Spectral AI represents a promising player in the med-tech sector, harnessing the power of AI to address complex diagnostic challenges. By narrowing the gap between technological advancements and practical medical applications, Spectral AI exemplifies the evolving role of AI in modern medicine, marking its significance as a transformative force in healthcare diagnostics on the global stage.
CEO Mr. Vincent Stanley Capone Esq. · 65 employees · United States · https://www.spectral-ai.com